The Globe and Mail reports in its Friday, May 16, edition that National Bank Financial analyst Maxim Sytchev has reaffirmed his "outperform" recommendation for Atkinsrealis Group. The Globe's David Leeder writes in the Eye On Equities column that Mr. Sytchev gave his share target a $4 boost to $92. Analysts on average target the shares at $92.77. Atkinsrealis on Thursday reported revenue for the quarter of $2.54-billion, above both Mr. Sytchev's estimate at $2.26-billion and the Street's forecast at $2.39-billion. Mr. Sytchev says in a note: "On balance, this is a good start to the year, driven by nuclear; engineering growth will resume given backlog additions that we saw this quarter. Cash from the 407 sale will, of course, only further solidify the balance sheet while also dramatically simplifying the reporting/analytical structure of the company, hopefully driving down the discrepancy between Atkinsrealis valuation and that of its direct peers. Stock's move upward [Thursday] morning is deserving, in our view, but maybe not the entire 12 per cent. Further rerate is a function of multiple expansion, supported by NCIB and resumption of growth in the engineering space."